Zydus Life rises on USFDA nod for heart failure drug 0 10.07.2024 13:06 Business Standard Zydus Lifesciences gained 1.81% to Rs 1187.15 after the company announced that it has received a final approval from the United States Food and Drug Administration (USFDA) to market Sacubitril and Valsartan tablets. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
